(Q37871407)

English

Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer

scientific article published on 03 May 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

estrogen-receptor positive breast cancer

0 references

1 reference

based on heuristic

inferred from title

Eleftherios P Mamounas

2

object named as

Eleftherios P Mamounas

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

author name string

Jessica F Partin

1

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

publication date

3 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Annals of Surgical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

3399-3406

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1698-Z

21 January 2018

Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1698-Z

21 January 2018

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1698-Z

21 January 2018

A gene-expression signature as a predictor of survival in breast cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1698-Z

21 January 2018

Gene expression profiling predicts clinical outcome of breast cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1698-Z

21 January 2018

Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1698-Z

21 January 2018

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1698-Z

21 January 2018

A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1698-Z

21 January 2018

HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1698-Z

21 January 2018

A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1698-Z

21 January 2018

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1698-Z

21 January 2018

A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1698-Z

21 January 2018

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1698-Z

21 January 2018

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1698-Z

21 January 2018

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1698-Z

21 January 2018

A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1698-Z

21 January 2018

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1698-Z

21 January 2018

Histopathologic variables predict Oncotype DX recurrence score

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1698-Z

21 January 2018

Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1698-Z

21 January 2018

Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1698-Z

21 January 2018

The influence of a gene expression profile on breast cancer decisions

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1698-Z

21 January 2018

Development of the 21-gene assay and its application in clinical practice and clinical trials

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1698-Z

21 January 2018

Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1698-Z

21 January 2018

Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1698-Z

21 January 2018

Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1698-Z

21 January 2018

Identifiers

10.1245/S10434-011-1698-Z

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37871407&oldid=2201038179"